Skip to main content
. Author manuscript; available in PMC: 2012 May 1.
Published in final edited form as: Eur J Immunol. 2011 Apr 12;41(5):1465–1479. doi: 10.1002/eji.201041241

Figure 2. Specificity of recombinant Fab Ab phage clones selected on DR2/MOG-35-55 complexes (RTL1000).

Figure 2

A) Representative supernatant ELISA of Fab clones selected against RTL1000. The boxed areas and arrows indicate Fabs that specifically bind to the DR2/MOG-35-55 complex but not to a control DR2 complex containing the DR2-restricted MBP peptide (RTL340). These clones were picked for further characterization. B) ELISA binding of soluble purified Fabs to immobilized DR2/MOG-35-55 complex in the presence of various concentrations of the following competitors: DR2/MOG-35-55, DR2/MBP-85-99, MOG-35-55 peptide, or MBP-85-99 peptide. Data are representative of three independent experiments C) ELISA binding of the indicated soluble purified Fabs and anti-MHC II mAb TU39 (BD) to immobilized DR2/MOG-35-55, control complexes, and MOG-35-55 peptide. Data are representative of four independent experiments